Author: Sudarshana Datta, M.D.

A 5% Absolute Increase in Influenza Activity Associated with a 24% Increase in Heart Failure Hospitalizations, According to New Study
Heart Failure, News

A 5% Absolute Increase in Influenza Activity Associated with a 24% Increase in Heart Failure Hospitalizations, According to New Study

A study conducted by Sonja Kytömaa and Sheila Hegde of the cardiovascular division, Brigham and Women’s Hospital, Boston, Massachusetts, reported that influenza... Read more.
STOPDAPT-2 Explores Safety and Efficacy of 1-month DAPT Followed by Clopidogrel Monotherapy vs Standard 12-month DAPT After Drug-Eluting Stent Implantation
ACC 2019, Acute Coronary Syndrome, Cardiovascular Prevention, Clinical Trials, Conferences, News, Prevention

STOPDAPT-2 Explores Safety and Efficacy of 1-month DAPT Followed by Clopidogrel Monotherapy vs Standard 12-month DAPT After Drug-Eluting Stent Implantation

The results of the STOP-DAPT 2 randomized controlled trial were presented by Dr. Hirotoshi Watanabe at the American College of Cardiology Annual Scientific Session... Read more.
TREAT Trial Addresses the Safety and Efficacy of Ticagrelor Use for STEMI Management in the Setting of Fibrinolytic Therapy
Cardiovascular Prevention, Clinical Trials, Conferences, Interventional Cardiology, News

TREAT Trial Addresses the Safety and Efficacy of Ticagrelor Use for STEMI Management in the Setting of Fibrinolytic Therapy

According to the results of the TREAT trial, among patients aged under 75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly... Read more.
Total Event Analysis from REDUCE-IT Showcases a Substantial Reduction in the Burden of Ischemic Events, Experts Debate Possible Mechanisms of Action of Icosapent Ethyl
Atherosclerotic Cardiovascular Disease, Cardiovascular Prevention, Clinical Trials, Conferences, FDA, Lipid Lowering Therapy, News, Statins

Total Event Analysis from REDUCE-IT Showcases a Substantial Reduction in the Burden of Ischemic Events, Experts Debate Possible Mechanisms of Action of Icosapent Ethyl

The total event analysis from the REDUCE-IT trial, presented at ACC 2019 showed that among statin-treated patients with elevated triglycerides and cardiovascular... Read more.
AUGUSTUS: Less Bleeding and Fewer Hospitalizations Without Significant Differences in Ischemic Events With Apixaban and No Aspirin in Patients With AFib and ACS
Acute Coronary Syndrome, Atrial Fibrillation, Clinical Trials, Conferences, News

AUGUSTUS: Less Bleeding and Fewer Hospitalizations Without Significant Differences in Ischemic Events With Apixaban and No Aspirin in Patients With AFib and ACS

ACC 2019: In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included... Read more.
HeartMate3 Found to be More Superior Than Other LVADs on Endpoints of Stroke, Pump Thrombosis and Bleeding Complications
Clinical Trials, Conferences, FDA, Heart Failure, News

HeartMate3 Found to be More Superior Than Other LVADs on Endpoints of Stroke, Pump Thrombosis and Bleeding Complications

The largest LVAD trial ever to be performed, led by Dr. Mandeep Mehra published the final analysis of a fully magnetically levitated left ventricular assist device... Read more.
HEARTLINE: A 180,000 Patient-Strong, Pragmatic, Real World Randomized Trial Assesses the Prowess of Apple Technology in Afib Diagnosis and Improvement of Hard Outcomes
Arrhythmia and Electrophysiology, Atrial Fibrillation, Cardiovascular Prevention, Clinical Trials, Conferences, News

HEARTLINE: A 180,000 Patient-Strong, Pragmatic, Real World Randomized Trial Assesses the Prowess of Apple Technology in Afib Diagnosis and Improvement of Hard Outcomes

The design of the HEARTLINE randomized trial of up to 180,000 pts for assessing the efficacy of the Apple Watch & educational initiatives to reduce a composite... Read more.
Findings From a Randomized Controlled Trial May Usher the Adoption of Angiotensin–Neprilysin Inhibition to the Heart-Failure Armamentarium
Clinical Trials, Conferences, Heart Failure, News, NT-ProBNP

Findings From a Randomized Controlled Trial May Usher the Adoption of Angiotensin–Neprilysin Inhibition to the Heart-Failure Armamentarium

The results of a trial presented by Dr. Adam DeVore at the American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, reflected that among... Read more.